Publications by authors named "F Rony"
Article Synopsis
- COPD is a chronic inflammatory lung disease, and there's a need for new anti-inflammatory treatments, particularly those targeting the PI3K pathway, with CHF6523 being an inhaled PI3Kδ inhibitor showing promise in preliminary tests.
- The study involved 44 patients with stable COPD, using a randomized double-blind design with two treatment phases over 28 days each, to evaluate the safety, tolerability, and pharmacokinetics of CHF6523 compared to a placebo.
- Results indicated that CHF6523 effectively reduced a key inflammatory marker (PIP) by 29.7% from baseline, with pharmacokinetic data suggesting limited drug accumulation and quick absorption after inhalation.
Article Synopsis
- The text discusses the transition from high global warming potential propellants in metered-dose inhalers (MDIs) to those with lower environmental impact, specifically investigating a new formulation of BDP/FF/GB using HFA-152a instead of HFA-134a.
- Three studies were conducted to compare the pharmacokinetics of the new formulation, focusing on metrics like lung availability and systemic exposure in healthy volunteers, using a crossover design.
- Results showed that bioequivalence was achieved for systemic exposure of the active ingredients in most cases, but not for one measurement of glycopyrronium bromide, indicating some variability in absorption.
An extrafine formulation triple therapy combination of beclomethasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) has been developed for the maintenance treatment of asthma and chronic obstructive pulmonary disease. This study used gamma scintigraphy to evaluate the intrapulmonary and extrapulmonary deposition of BDP/FF/GB, and the intrapulmonary regional distribution of the deposited formulation. This open-label uncontrolled nonrandomized single-dose study recruited 10 healthy volunteers and 9 patients with asthma.
View Article and Find Full Text PDFPurpose: To evaluate the kinetics of topically applied clobetasol-17-propionate (CP-17) in lesional and non-lesional psoriatic skin when released from a commercially available low-strength cream using in vivo dermal open-flow microperfusion (dOFM).
Methods: Twelve patients received Dermovate® cream (CP-17, 0.05%) on small lesional and non-lesional skin test sites for 14 days, once daily.
Background: Persistent facial erythema is the most common primary pathological feature of rosacea, the only treatment for which is brimonidine tartrate (BT) gel.
Objectives: To assess the relative bioavailability of topical BT gel in comparison with the ophthalmic BT solution.
Methods: A pharmacokinetic study was conducted to compare intraindividual systemic exposures after dermal application of BT gel (0·07%, 0·18% and 0·5%) under maximal use conditions in patients with moderate-to-severe facial erythema associated with rosacea, and administration of BT ophthalmic solution 0·2%.